港股异动 | 来凯医药-B(02105)再涨超11% 新药LAE102临床试验申请获受理
来凯医药-B(02105)再涨超11%，近三个交易日该股累涨超70%。截至发稿，涨9.2%，报6.29港元，成交额3131.4万港元。
消息面上，来凯医药公布，中国国家药品监督管理局的药品审评中心已受理了针对LAE102的新药临床试验申请，该药物是来凯自主研发针对ActRIIA的单克隆抗体，用于治疗成人肥胖或代谢性疾病患者。公司方面表示，在获得IND批准后，将启动临床试验流程。
华创证券此前指出，全球首创的ActRIIA单抗LAE102能够增肌减脂，有潜力和GLP-1RA配合使用，市场潜力巨大并具备国际化价值。长城证券也认为，以增肌减脂药物LAE102 为代表的自研管线具备良好成药前景，看好公司未来长期发展。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.